Current status and progress in immunotherapy for malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Current status and progress in immunotherapy for malignant pleural mesothelioma

Published:2022-03-31 Issue:2 Volume:8 Page:91-99
ISSN:2589-0514
Container-title:Chronic Diseases and Translational Medicine
language:en
Short-container-title:Chronic Diseases and Translational Medicine

Author:

Sun Boyang¹,Dong Yiting¹,Xu Jiachen¹,Wang Zhijie¹

Affiliation:

1. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021 China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cdt3.18

Reference50 articles.

1. Malignant pleural mesothelioma: The standard of care and challenges for future management

2. Global Asbestos Disaster

3. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation

4. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature

5. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amphibian-Derived Natural Anticancer Peptides and Proteins: Mechanism of Action, Application Strategies, and Prospects;International Journal of Molecular Sciences;2023-09-12

2. Modulation of Transcription Profile Induced by Antiproliferative Thiosemicarbazone Metal Complexes in U937 Cancer Cells;Pharmaceutics;2023-04-24

3. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma;Frontiers in Immunology;2023-03-17